Markets
BSE See NSE See 39,046.34
85.55 (0.22%)
collapse Related Readings collapse

Stock Pick From The Plastic Industry

| 6/14/2012 9:00 PM Thursday

Choice Scrip is a Blue Chip stock pick that is expected to give returns within a 6 months-1 year horizon. The recommendation is based on a fundamental analysis of the company.

The company recommended as the Choice Scrip for this issue is a market leader in the absolac market, which is a plastic resin produced from acrylonitrile, butadiene and styrene (ABS).

Styrolution ABS- Plastic Potential

  • SABS is a market leader with a 65 per cent market share in the absolac market, which is a plastic resin produced from acrylonitrile, butadiene and styrene (ABS).
  • It is a debt-free company with a strong performance, which is expected to get even stronger as the demand from user industries goes up further.
  • Anticipating a growth in demand, the company recently expanded its capacity from 60000 mtpa to 80000 mtpa, and is in the process of further increasing its capacity to 110000 mtpa by 2014.

Fundamentally strong and consistently dividend paying companies make for good investment ideas during volatile market times. One such idea that we are presenting to our readers as our Choice Scrip for this fortnight is Styrolution ABS (SABS), formerly known as Ineos ABS India. This is a company which fulfils both the above conditions. Not only is it a fundamentally strong company, it is also one which has been consistently paying dividends for the past 22 years.

While its strong dividend payment track record is just one of the factors that makes this stock worth recommending, there are a number of others too that go in its favour. SABS is a market leader with a 65 per cent market share in the absolac market, which is a plastic resin produced from acrylonitrile, butadiene and styrene (ABS). It is a widely used intermediary product finding application in a host of industries, including home appliances, automobiles, consumer durables and business machines.

BEST OF LAST ONE YEAR

Company Name

Reco.

CMP (Rs)

 Gain %

Ajanta Pharma

342.00

626.00

83.04

Asian Paints

2985.00

3890.00

30.32

Nestle India

3746.85

4460.00

19.03

FAG Bearings India

1261.00

1473.00

16.81

Suprajit Engineering

19.80

22.50

13.64

Munjal Showa

71.50

81.00

13.29

Colgate Palmolive (I)

1014.00

1132.00

11.64

Torrent Pharmaceuitical

559.00

605.00

8.23

CMP as on June 12, 2012 

This is a debt-free company with a strong performance, which is expected to get even stronger as the demand from user industries goes up further. The company has already expanded its capacity to cater to this increased demand.

SABS enjoys a strong management bandwidth, which comes primarily from its MNC parentage. The management believes that India has an advantage as a major engineering thermoplastics manufacturing hub in Asia. The current rate of growth of this market hints at the good prospects that the industry has going forward. Anticipating this growth in demand, the company recently expanded its capacity from 60000 mtpa to 80000 mtpa, and is in the process of further increasing its capacity to 110000 mtpa by 2014.

There are certain added advantages that SABS enjoys by virtue of INEOS (its parent company) being a global company. First, INEOS has ABS manufacturing facilities at US, Germany, Spain and Thailand, and the combined capacity makes it the third largest ABS manufacturer in the world. Not only does this help SABS to add new products to its kitty, but it also helps the company procure raw materials (which is mostly imported) in an efficient manner. Being derivatives of crude, the prices of its raw material are highly volatile and efficient procurement of the same helps it to improve its margins. Power also forms a substantial part of the company’s operational costs. The fact that SBS owns 14 windmills with a capacity of producing 8.60 MW of power (provided to the grid) provides it with an advantage, reducing the net cost of power.

In CY11, its topline stood at Rs 825 crore and the bottomline stood at Rs 54.99 crore as against Rs 742 crore and Rs 70 crore respectively for CY10. The profitability was lower on account of the increase in crude prices and higher forex losses (Rs 12 crore in CY11 versus Rs 1.38 crore in CY10). However, we believe that this is an extraordinary event, and that with a fall in the crude oil prices and the expected appreciation of the rupee in the remaining part of CY12, coupled with a rise in demand, the company will improve on its performance. On the valuations front, at its CMP of Rs 719, the scrip discounts its CY11 earnings by 23x and its EV/EBITDA stands at 11.5x. Given the growth prospects of the company, the scrip demands a higher valuation. Therefore, we recommend that investors buy the scrip at thecurrent levels with a target price of Rs 870 in the next one year.

Share Holding Pattern as on 31/3/2012

Promoters

87.3

Banks Fin. Inst. and Insurance

0.15

FII

0.66

Private Corporate Bodies

2.1

Others

0.31

General Public

9.45

GRAND TOTAL

100.0


LAST FIVE QUARTERS (R/CR)

Particulars

Mar ' 12

Dec ' 11

Sep ' 11

Jun ' 11

Mar ' 11

Net Sales

235.81

211.24

207.78

206.3

201.08

Raw Material

174.16

178.44

152.43

165.52

143.48

Other Expenses

26.85

25.74

24.4

22.29

27.36

Operating Profit

22.82

13.43

12.37

24.25

31.05

Taxation

7.7

2.87

3.2

7.6

9.85

Net Profit / Loss

16.08

9.59

8.35

15.84

20.19

Equity Capital

17.59

17.59

17.59

17.59

17.59

 

 

Find More Articles on: Stock Recommendations, Fundamental Picks, DSIJ Magazine, Choice Scrip, Product, Mid Cap, Small Cap

news letter

More for the early bird.

Get the post-market reports and breakfast news right in your inbox. See latest »

DSIJ Mindshare

MIDHANI and HAL partner to develop bio implants

Geyatee Deshpande / Article rating: 5.0

Mishra Dhatu Nigam Limited (MIDHANI) signs an MoU with Hindustan Antibiotics Limited (HAL). This MoU will provide synergy for quality manufacturing of MIDHANI’s Bio-medical Implants and get access to the pan-India distribution of HAL. This partnership is aimed to gain advantage from the strengths of both the companies and benefit users of Bio-medical products in India.

12345678910Last

Tiger Logistics topline to grow by 10%--buoyant over infra sector status to logistics sector

Tiger Logistics topline to grow by 10%--buoyant over infra sector status to logistics sector

Logistics sector will play a vital role in making the concept of ‘Make in India’ a success. This will be further aided by some of the recent steps taken by Government of India such as granting of infra sector status to logistics sector.

Best and worst Performing Sector Funds of Year 2017

Best and worst Performing Sector Funds of Year 2017

As the year-end has approached most of you are eager to know the mutual fund movers and shakers of the year 2017. Read on to find the performance of various sector dedicated funds.

Markets may start positive, but volatility likely due to F&O expiry

Markets may start positive, but volatility likely due to F&O expiry

The start of the F&O expiry day is likely to be in the green, but volatility may creep in with the progress of the session. The SGX Nifty suggests that the Nifty could open at 10,525 with gains of 32 points at the opening bell. 

Pidilite announces buyback of Rs 500 crore

Pidilite announces buyback of Rs 500 crore

The buyback offer comprises purchase of up to 50,00,000 equity shares. The buyback offer size comprises 0.975 per cent of the total paid-up equity capital of the company.

Bank Nifty drags markets to close in the red

Bank Nifty drags markets to close in the red

The late session fall in Bank Nifty changed the direction of the market, leading to a marginal fall in the benchmark indices. Bank Nifty yet again resisted at its multiple point downward sloping trendline level at 25733.

Six major underperforming MF schemes having higher expense ratios

Six major underperforming MF schemes having higher expense ratios

Mutual funds with a large size of assets under management (AUMs) are supposed to have lower expense ratios. However, there are schemes with large AUMs but having higher expense ratios and generating lower returns. 

Nifty Pharma supports market; Sun Pharma at bullish reversal

Nifty Pharma supports market; Sun Pharma at bullish reversal

Nifty Pharma index has come in as the healer in an otherwise sluggish market. Index has given a consolidation breakout at the 9420 level today and if the it sustains 9420, followed by 9628 on the upside, it has a long way to go.

Ten stocks close to their 52-week low

Ten stocks close to their 52-week low

Following stocks are close to their 52-week low as at 12.35 p.m. on December 27.

Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

The markets on December 27 opened gap down. BSE Sensex is trading at 34,068.15, up by 57.54 points and the Nifty is trading at 10,539.45, up by 7.95 points.

Five stocks with selling interest

Five stocks with selling interest

Overall volumes in futures & options currently stand at 62.75 lakh contracts with a turnover of Rs. 5,19,204.72 crore.